Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

Benzinga · 2d ago
Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $36 to $40.